Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, 52-weeks Study to Demonstrate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab Injections With 2 mL Pre-filled Syringes (300 mg) in Adult Subjects With Moderate to Severe Plaque Psoriasis

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, 52-weeks Study to Demonstrate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab Injections With 2 mL Pre-filled Syringes (300 mg) in Adult Subjects With Moderate to Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms ALLURE
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

  • 25 Apr 2021 Primary endpoint (Participants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment) has been met, as per Results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
  • 25 Apr 2021 Primary endpoint (Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment) has been met, as per Results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
  • 25 Apr 2021 Results presented at the American Academy of Dermatology Virtual Meeting Experience 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top